Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2000
10/05/2000WO2000058467A1 50 human secreted proteins
10/05/2000WO2000058466A2 Protease resistant flint analogs
10/05/2000WO2000058361A1 Melanocortin receptor ligands
10/05/2000WO2000058356A1 50 human secreted proteins
10/05/2000WO2000058355A1 50 human secreted proteins
10/05/2000WO2000058350A1 49 human secreted proteins
10/05/2000WO2000058339A2 50 human secreted proteins
10/05/2000WO2000058337A1 Liver specific bile acid derivatives of the glucocorticoid antagonist ru486
10/05/2000WO2000058334A1 50 human secreted proteins
10/05/2000WO2000058311A1 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate and carboxamide derivatives, production and use thereof in therapeutics
10/05/2000WO2000058307A2 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands
10/05/2000WO2000058305A1 Novel compounds
10/05/2000WO2000058293A2 Glucokinase activators
10/05/2000WO2000058285A1 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders
10/05/2000WO2000058279A1 Diaryl derivatives and their use as medicaments
10/05/2000WO2000057921A2 Peroral gene therapy of diabetes and obesity
10/05/2000WO2000057920A2 Method for expressing proteins
10/05/2000WO2000057918A2 Novel formulations comprising lipid-regulating agents
10/05/2000WO2000057915A1 Method of affecting cholesterol catabolism using nuclear bile acid receptor
10/05/2000WO2000057898A1 Compositions for reducing blood cholesterol
10/05/2000WO2000057865A2 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
10/05/2000WO2000057864A2 Cyclic glycerophosphates and analogs thereof
10/05/2000WO2000057859A1 Novel formulations comprising lipid-regulating agents
10/05/2000WO2000057837A2 Compositions and methods for effecting the levels of cholesterol
10/05/2000WO2000057720A1 Method for selectively altering body fat level, feed efficiency, or weight gain
10/05/2000WO2000042026B1 Non-peptide glp-1 agonists
10/05/2000WO2000032178A3 Use of siburamine for the treatment of disorders of the central nervous system secondary to organic impairments
10/05/2000WO2000030624A3 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus
10/05/2000WO2000005249A3 Synthetic peptides and methods of use for autoimmune disease therapies
10/05/2000WO1998041232A3 Compositions for modulating responsiveness to corticosteroids
10/05/2000CA2383592A1 2384891 acids including open reading frames encoding polypeptides; orfx
10/05/2000CA2369458A1 47 human secreted proteins
10/05/2000CA2368951A1 50 human secreted proteins
10/05/2000CA2368881A1 50 human secreted proteins
10/05/2000CA2368719A1 50 human secreted proteins
10/05/2000CA2368700A1 49 human secreted proteins
10/05/2000CA2368597A1 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
10/05/2000CA2368489A1 50 human secreted proteins
10/05/2000CA2368467A1 50 human secreted proteins
10/05/2000CA2368302A1 49 human secreted proteins
10/05/2000CA2368281A1 50 human secreted proteins
10/05/2000CA2368234A1 Method of affecting cholesterol catabolism using nuclear bile acid receptor
10/05/2000CA2368113A1 Protozoan expression system
10/05/2000CA2367995A1 Novel formulations comprising lipid-regulating agents
10/05/2000CA2367792A1 Liver specific bile acid derivatives of the glucocorticoid antagonist ru486
10/05/2000CA2366305A1 Method for expressing proteins
10/05/2000CA2365995A1 Cyclic glycerophosphates and analogs thereof
10/05/2000CA2365401A1 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands
10/05/2000CA2365128A1 Novel formulations comprising lipid-regulating agents
10/05/2000CA2364417A1 Peroral gene therapy of diabetes and obesity
10/05/2000CA2361366A1 Novel compounds
10/05/2000CA2361016A1 Diaryl derivatives and their use as medicaments
10/04/2000EP1041072A1 Dioxocyclopentyl hydroxamic acids
10/04/2000EP1041068A1 Compounds for treating and preventing diabetic complications
10/04/2000EP1041064A2 N-substituted alpha aminoacid amides as calcium channel modulators
10/04/2000EP1040827A2 Use of 2-alkylpyrrolidines for the treatment of diabetes
10/04/2000EP1040125A1 Glucose regulated gene
10/04/2000EP1040111A1 Integrin receptor antagonists
10/04/2000EP1040110A1 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione,maleic acid salt,hydrate as pharmaceutical
10/04/2000EP1040109A1 N-phenylamide and n-pyridylamide derivatives, method of preparing them and pharmaceutical compositions containing them
10/04/2000EP1040106A1 Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
10/04/2000EP1040102A1 Arylthiazolidinedione derivatives
10/04/2000EP1040101A1 Substituted 2-aryl-4-amino-chinazolines, method for the production and use thereof as medicaments
10/04/2000EP1040100A1 Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
10/04/2000EP1040099A1 Azepine or larger medium ring derivatives and their use as pharmaceuticals
10/04/2000EP1040098A1 Integrin receptor antagonists
10/04/2000EP1039934A1 Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders
10/04/2000EP1039920A1 Fatty acid-acylated insulin analogs
10/04/2000EP1039919A1 Composition for improving mental capabilities in mammals
10/04/2000EP1039915A1 Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
10/04/2000EP1039900A2 Pharmaceutical composition containing sibutramine and orlistat
10/04/2000EP1039893A1 Pharmaceutical compositions containing an omega-3 fatty acid oil
10/04/2000EP1039890A1 Novel salts of metformin and method
10/04/2000EP1019040A4 INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS
10/04/2000EP0690719B1 Dry mix formulation for bisphosphonic acids
10/04/2000CN1268889A Novel process for obtg. intermediates
10/04/2000CN1268869A Satiety product
10/04/2000CN1268357A Fat-reducing liver-fortifying mixture
10/04/2000CN1057098C Glucagon-like peptide and insulinotropin derivatives
10/04/2000CN1057013C Novel 1 L-2 receptor-specific human immunoglobins
10/04/2000CN1056980C Compound balson pear capsules for curing diabetes, and prepn. method thereof
10/03/2000US6127522 CRFG-1a, a target and marker for chronic renal failure
10/03/2000US6127519 Calcitonin derivatives
10/03/2000US6127426 Antiallergic and -inflammatory agents e.g., treating psoriasis, blocked on the c-10 by a nonphenolic arylacyl or a phenylalkylidene group; lipoxygenase inhibitors; antiproliferative agents; low dosage; side effect reduction
10/03/2000US6127424 Aryl-substituted cyclobutylalkylamines for treating obesity
10/03/2000US6127414 Antagonists of neuropeptide y and, in particular, in the treatment of cardiovascular diseases, e.g., vasoconstriction; hypotensive agents
10/03/2000US6127404 Tissue selective compounds in the treatment of endometrial proliferation
10/03/2000US6127403 An enzyme inhibitor for treating arteriosclerotic lesions of arteriosclerosis, hyperlipemia and diabetes, as well as ischemic diseases of brain, heart
10/03/2000US6127398 An enzyme inhibitor for the inhibition of phosphodiesterase typeiv or the production of tumor necrosis factor in a mammal; treating asthma, arthritis, bronchitis, chronic obstructive airway disease, psoriasis, allergic rhinitis
10/03/2000US6127396 Imidazoline compounds
10/03/2000US6127391 Compounds with growth hormone releasing properties
10/03/2000US6127389 Benzimidazole derivatives as bradykinin agonists
10/03/2000US6127383 Treatment of arteriosclerosis
10/03/2000US6127382 An antiproliferative agent for treating skin-related diseases, an antitumor agent treating cancer, an antiinflammatory agent treating pulmonary fibrosis, ileitis, colitis and krohn's disease
10/03/2000US6127376 Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
10/03/2000US6127367 Administering an aldose reductase inhibitor as an antiischemic agent
10/03/2000US6127348 Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
10/03/2000US6127338 Three peptides of given amino acid sequences with antihyperglycemic activity; extracts of the fruit momordica charantia
10/03/2000US6126941 Phospholipidic composition, method for the production of such a composition and its use
10/03/2000CA2274630C Preparation of ¬1s-¬1a,2b,3b,4a(s*)||-4-¬7-¬¬1-(3-chloro-2-thienyl) methyl|propyl|amino|-3h-imidazo¬4,5-b|pyridin-3-yl|-n-ethyl-2,3-dihydroxycyclopentanecarboxamide
1 ... 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 ... 1298